Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application ...

Bristol Myers Squibb’sBMY performance in 2025 reflects an ongoing transition in its revenue base, with growth from newer products partially offsetting continued declines in legacy drugs. Sales from ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

Bristol Myers Squibb and its subsidiary Karuna Therapeutics received the latest Untitled Letter from the Food and Drug Administration earlier this week. In a letter issued on December 15 to Nicole Van ...

Medicare drug price negotiations kick-started by the Biden administration will finally result in lower drug prices for seniors beginning Jan. 1. The Medicare-negotiated price cuts will apply to 10 ...

One is a sector mainstay that has now raised its payout 17 years in a row. The other is a big player in the animal healthcare space. It's not too late to take advantage of either. The healthcare ...

Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug ...

We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer's radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the ...